期刊
EUROPEAN NEUROPSYCHOPHARMACOLOGY
卷 23, 期 2, 页码 79-88出版社
ELSEVIER
DOI: 10.1016/j.euroneuro.2012.04.013
关键词
Testosterone; Brain; Neuroimaging; Sex differences; Androgen; PET; fMRI
资金
- AstraZeneca
- Bristol-Myers Squibb
- CSC
- Eli Lilly
- GlaxoSmithKline
- Janssen
- Lundbeck
- Merck Sharp and Dome (MSD)
- Novartis
- Organon
- Pierre Fabre
- Pfizer
- Schwabe
- Sepracor
- Servier
- Wyeth
- H. Lundbeck A/S
Testosterone plays a substantial role in a number of physiological processes in the brain. It is able to modulate the expression of certain genes by binding to androgen receptors. Acting via neurotransmitter receptors, testosterone shows the potential to mediate a non-genomic so-called neuroactive effect. Various neurotransmitter systems are also influenced by the aromatized form of testosterone, estradiol. The following article summarizes the findings of preclinical and clinical neuroimaging studies including structural and functional magnetic resonance imaging (MRI/fMRI), voxel based morphometry (VBM), as well as pharmacological fMRI (phfMRI) and positron emission tomography (PET) regarding the effects of testosterone on the human brain. The impact of testosterone on the pathogenesis of psychiatric disorders and on sex-related prevalence differences have been supported by a wide range of clinical studies. An antidepressant effect of testosterone can be implicitly explained by its effects on the limbic system - especially amygdala, a major target in the treatment of depression - solidly demonstrated by a large body of neuroimaging findings. (c) 2012 Elsevier B.V. and ECNP. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据